|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Provision for credit losses | |||||
| Depreciation | |||||
| Net amortization of premium and discounts on loans, securities, deposits and debt obligations | |||||
| Amortization of mortgage servicing rights, net of impairment charges/recoveries | |||||
| Amortization of intangibles | |||||
| Mortgage banking gain, net | |||||
| Gain on sale of insurance agency, net | |||||
| Loss (Gain) on sale / write-down of real estate and other assets held for sale | |||||
| Gain on sale of available for sale securities | |||||
| (Gain) loss on equity securities | |||||
| Change in deferred taxes | |||||
| Proceeds from sale of loans held for sale | |||||
| Origination of loans held for sale | |||||
| Stock based compensation expense | |||||
| Restricted stock forfeits for taxes and option exercises | |||||
| Income from bank owned life insurance | |||||
| Accrued interest receivable and other assets | |||||
| Other liabilities | |||||
| Net cash provided by operating activities | |||||
| Investing Activities | |||||
| Proceeds from maturities, calls and paydowns of available-for-sale securities | |||||
| Proceeds from sale of available-for-sale securities | |||||
| Proceeds from sale of equity securities | |||||
| Proceeds from sale of OREO | |||||
| Purchases of available-for-sale securities | |||||
| Purchases of equity securities | |||||
| Purchases of office properties and equipment | |||||
| Investment in bank owned life insurance | |||||
| Proceeds from bank owned life insurance death benefit | |||||
| Net change in Federal Home Loan Bank stock | |||||
| Proceeds from sale of non-mortgage loans | |||||
| Net cash received in disposition (paid in acquisition) | |||||
| Net decrease (increase) in loans receivable | |||||
| Net cash provided by (used in) investing activities | |||||
| Financing Activities | |||||
| Net (decrease) increase in deposits and advance payments by borrowers | |||||
| Net change in Federal Home Loan Bank advances | |||||
| Proceeds from subordinated debentures | |||||
| Decrease in securities sold under repurchase agreements | |||||
| Cash dividends paid on common stock | |||||
| Net cash paid for repurchase of common stock | |||||
| Proceeds from exercise of stock options | |||||
| Proceeds from direct stock sales | |||||
| Net cash (used in) provided by financing activities | |||||
| Increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of period | |||||
| Cash and cash equivalents at end of period | |||||
| Supplemental cash flow information: | |||||
| Interest paid | |||||
| Income taxes paid | |||||
| Transfers from loans to other real estate owned and other assets held for sale | |||||
| Initial recognition of right-of-use asset | |||||
| Initial recognition of lease liability | |||||
| Initial recognition ASU 326 | |||||
Loading...
